Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Research & Development: 2011-2025

Historic Research & Development for Sunshine Biopharma (SBFM) over the last 5 years, with Sep 2025 value amounting to $119,298.

  • Sunshine Biopharma's Research & Development fell 5.59% to $119,298 in Q3 2025 from the same period last year, while for Sep 2025 it was $680,079, marking a year-over-year decrease of 57.52%. This contributed to the annual value of $933,902 for FY2024, which is 49.68% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Research & Development of $119,298 as of Q3 2025, which was down 39.21% from $196,232 recorded in Q2 2025.
  • Sunshine Biopharma's 5-year Research & Development high stood at $816,328 for Q4 2023, and its period low was $41,763 during Q4 2022.
  • Moreover, its 3-year median value for Research & Development was $222,033 (2024), whereas its average is $301,867.
  • As far as peak fluctuations go, Sunshine Biopharma's Research & Development surged by 5,177.66% in 2021, and later plummeted by 81.71% in 2024.
  • Sunshine Biopharma's Research & Development (Quarterly) stood at $91,198 in 2021, then tumbled by 54.21% to $41,763 in 2022, then soared by 1,854.67% to $816,328 in 2023, then crashed by 81.71% to $149,272 in 2024, then fell by 5.59% to $119,298 in 2025.
  • Its Research & Development stands at $119,298 for Q3 2025, versus $196,232 for Q2 2025 and $215,277 for Q1 2025.